Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.75 [0.64, 0.87] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | crucial | - |
deaths (OS) (extension) | 0.66 [0.55, 0.80] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
PFS (extension) | 0.68 [0.57, 0.82] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
progression or deaths (PFS) | 0.72 [0.61, 0.86] | | < 1 | | 44% | 3 studies (3/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
objective responses (ORR) | 1.68 [1.24, 2.26] | | > 1 | | 53% | 3 studies (3/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
STRAE (any grade) | 2.05 [1.63, 2.59] | | < 1 | | 0% | 3 studies (3/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
STRAE (grade 3-4) | 2.00 [1.55, 2.58] | | < 1 | | 0% | 3 studies (3/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
TRAE (any grade) | 1.06 [0.60, 1.89] | | < 1 | | 77% | 3 studies (3/-) | 41.6 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) | 1.14 [0.87, 1.49] | | < 1 | | 47% | 3 studies (3/-) | 17.6 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to death (grade 5) | 1.07 [0.47, 2.45] | | < 1 | | 0% | 2 studies (2/-) | 43.5 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to discontinuation (any grade) | 3.22 [2.38, 4.36] | | < 1 | | 0% | 3 studies (3/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to discontinuation (grade 3-4) | 3.77 [2.59, 5.49] | | < 1 | | 0% | 3 studies (3/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
Adrenal insufficiency TRAE (grade 3-4) | 7.88 [0.41, 149.53] | | < 1 | | 0% | 1 study (1/-) | 8.7 % | NA | not evaluable | | non important | - |
Anaemia TRAE (grade 3-4) | 0.23 [0.10, 0.52] | | < 1 | | 60% | 3 studies (3/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
Asthenia TRAE (grade 3-4) | 0.78 [0.34, 1.75] | | < 1 | | 1% | 3 studies (3/-) | 72.9 % | some concern | not evaluable | moderate | non important | - |
Colitis TRAE (grade 3-4) | 9.87 [0.54, 181.39] | | < 1 | | 0% | 1 study (1/-) | 6.4 % | NA | not evaluable | | non important | - |
Constipation TRAE (grade 3-4) | 0.80 [0.09, 6.87] | | < 1 | | 0% | 3 studies (3/-) | 58.0 % | some concern | not evaluable | moderate | non important | - |
Decreased appetite TRAE (grade 3-4) | 0.80 [0.33, 1.97] | | < 1 | | 0% | 3 studies (3/-) | 68.5 % | some concern | not evaluable | moderate | non important | - |
Diarrhoea TRAE (grade 3-4) | 3.66 [1.44, 9.30] | | < 1 | | 0% | 3 studies (3/-) | 0.3 % | some concern | not evaluable | moderate | non important | - |
Fatigue TRAE (grade 3-4) | 1.64 [0.47, 5.72] | | < 1 | | 45% | 3 studies (3/-) | 21.9 % | some concern | not evaluable | moderate | non important | - |
Febrile neutropenia TRAE (grade 3-4) | 1.38 [0.60, 3.15] | | < 1 | | 0% | 1 study (1/-) | 22.3 % | NA | not evaluable | | non important | - |
Hypothyroidism TRAE (grade 3-4) | 1.57 [0.12, 20.54] | | < 1 | | 0% | 2 studies (2/-) | 36.6 % | some concern | not evaluable | moderate | non important | - |
Increased ALT TRAE (grade 3-4) | 2.46 [0.47, 12.75] | | < 1 | | 0% | 1 study (1/-) | 14.3 % | NA | not evaluable | | non important | - |
Increased lipase level TRAE (grade 3-4) | 7.55 [2.24, 25.47] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
Maculopapular rash TRAE (grade 3-4) | 4.93 [0.57, 42.41] | | < 1 | | 0% | 1 study (1/-) | 7.4 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 0.81 [0.26, 2.48] | | < 1 | | 29% | 3 studies (3/-) | 64.4 % | some concern | not evaluable | moderate | non important | - |
Neutropenia TRAE (grade 3-4) | 0.08 [0.00, 1.53] | | < 1 | | 83% | 3 studies (3/-) | 95.1 % | some concern | not evaluable | moderate | non important | - |
Pruritus TRAE (grade 3-4) | 4.84 [0.82, 28.43] | | < 1 | | 0% | 3 studies (3/-) | 4.1 % | some concern | not evaluable | moderate | non important | - |
Rash TRAE (grade 3-4) | 11.78 [2.19, 63.31] | | < 1 | | 0% | 3 studies (3/-) | 0.2 % | some concern | not evaluable | moderate | non important | - |
Thrombocytopenia TRAE (grade 3-4) | 1.09 [0.44, 2.70] | | < 1 | | 0% | 1 study (1/-) | 43.0 % | NA | not evaluable | | non important | - |
Vomiting TRAE (grade 3-4) | 0.34 [0.07, 1.74] | | < 1 | | 61% | 3 studies (3/-) | 90.2 % | some concern | not evaluable | moderate | non important | - |